

### Personal Transcription Factor Binding Site Mutations Point to Personal Medical Histories

**One GENOME to Rule Them All**

**Gill Bejerano**

STANFORD UNIVERSITY  
COMPUTER SCIENCE  
STANFORD Pediatrics  
SCHOOL OF MEDICINE

<http://bejerano.stanford.edu>

### Genome = Genes + Gene Regulation

**CIS REGULATION**

Type	# in genome	% of genome
genes	20,000	2%
ncRNA	20,000	1%
cis elements	1,000,000	>10%

- Encode causality
- Disease susceptibility
- Driver sequences
- Alter cell state
- Key for evolution

Atomic event – transcription factor binding

<http://bejerano.stanford.edu>

### Disease Associated tag SNPs

- Over 15,000 distinct tag SNPs in the GWAS Catalog
- 80-90% far away from (linkage with) gene exons
- Are most gene cis regulatory?
- Are they near genes with common functionality?

GWAS Catalog Growth

2008      2011      2016

<http://bejerano.stanford.edu>

### Cis-reg enrichments: GREAT.stanford.edu

½ million job submissions, 700+ references, established defaults

Gene transcription start site (π)      Gene regulatory domain (∇)

Function ('abnormal cardiac output')      Cis-reg rich region set

$p_* = 0.33$  of genome annotated with  $\pi$   
 $n = 6$  genomic regions  
 $k_* = 5$  genomic regions hit annotation

**GREAT = Genomic Regions Enrichment of Annotations Tool**

$P = Pr_{\text{binom}}(k_* \geq 5 \mid n=6, p_* = 0.33)$

[McLean et al, Nature Biotech, 2010]

<http://bejerano.stanford.edu/>

### Cis-reg enrichment: GREAT.stanford.edu

½ million job submissions, 700+ references, established defaults

Gene transcription start site (π)      Gene regulatory domain (∇)

Function ('abnormal cardiac output')      Cis-reg rich region set

**Advantages of GREAT:**

1. Accounts for both proximal and distal binding sites
2. Variable length gene regulatory domains
3. Multiple hits next to same gene add significance
4. Extensive body of knowledge (16,000 functions)

$p_* = 0.33$  of genome annotated with  $\pi$   
 $n = 6$  genomic regions  
 $k_* = 5$  genomic regions hit annotation

**GREAT = Genomic Regions Enrichment of Annotations Tool**

$P = Pr_{\text{binom}}(k_* \geq 5 \mid n=6, p_* = 0.33)$

[McLean et al, Nature Biotech, 2010]

<http://bejerano.stanford.edu/>

### Unlinked GWAS SNPs → GREAT

GWAS Phenotype	GREAT Annotated Gene	GREAT Workflows	# Enriched SNPs	P-value	Gene	Related Tissue	Function
Cholesterol level	LDLR	abnormal cholesterol cholesterol level	11	0.00	ABCA1, ABCG1, ABCG5, ABCG8, APOA1, APOA2, APOA3, APOA4, APOA5, APOA6, APOA7, APOA8, APOA9, APOA10, APOA11, APOA12, APOA13, APOA14, APOA15, APOA16, APOA17, APOA18, APOA19, APOA20, APOA21, APOA22, APOA23, APOA24, APOA25, APOA26, APOA27, APOA28, APOA29, APOA30, APOA31, APOA32, APOA33, APOA34, APOA35, APOA36, APOA37, APOA38, APOA39, APOA40, APOA41, APOA42, APOA43, APOA44, APOA45, APOA46, APOA47, APOA48, APOA49, APOA50, APOA51, APOA52, APOA53, APOA54, APOA55, APOA56, APOA57, APOA58, APOA59, APOA60, APOA61, APOA62, APOA63, APOA64, APOA65, APOA66, APOA67, APOA68, APOA69, APOA70, APOA71, APOA72, APOA73, APOA74, APOA75, APOA76, APOA77, APOA78, APOA79, APOA80, APOA81, APOA82, APOA83, APOA84, APOA85, APOA86, APOA87, APOA88, APOA89, APOA90, APOA91, APOA92, APOA93, APOA94, APOA95, APOA96, APOA97, APOA98, APOA99, APOA100	1%	

<http://bejerano.stanford.edu>

### Unlinked GWAS SNPs → GREAT

Phenotype	# SNPs	Associated SNPs	GREAT enrichment	# Functional SNPs	Peak	Ratio: Functional/All SNPs	Associated target genes	Fraction of affected SNPs
Cholesterol level	46	10	2.16 × 10 <sup>4</sup>	17	30.0%	0.15	ABCA1, ABCG1, ABCG5, ABCG8, APOA1, APOA2, APOA5, APOB, APOE, APOE2, APOE3, APOE4, APOE5, APOE6, APOE7, APOE8, APOE9, APOE10, APOE11, APOE12, APOE13, APOE14, APOE15, APOE16, APOE17, APOE18, APOE19, APOE20, APOE21, APOE22, APOE23, APOE24, APOE25, APOE26, APOE27, APOE28, APOE29, APOE30, APOE31, APOE32, APOE33, APOE34, APOE35, APOE36, APOE37, APOE38, APOE39, APOE40, APOE41, APOE42, APOE43, APOE44, APOE45, APOE46, APOE47, APOE48, APOE49, APOE50, APOE51, APOE52, APOE53, APOE54, APOE55, APOE56, APOE57, APOE58, APOE59, APOE60, APOE61, APOE62, APOE63, APOE64, APOE65, APOE66, APOE67, APOE68, APOE69, APOE70, APOE71, APOE72, APOE73, APOE74, APOE75, APOE76, APOE77, APOE78, APOE79, APOE80, APOE81, APOE82, APOE83, APOE84, APOE85, APOE86, APOE87, APOE88, APOE89, APOE90, APOE91, APOE92, APOE93, APOE94, APOE95, APOE96, APOE97, APOE98, APOE99, APOE100	2%
Height	38	10	3.24 × 10 <sup>4</sup>	10	26.3%	0.08	ABCA1, ABCG1, ABCG5, ABCG8, APOA1, APOA2, APOA5, APOB, APOE, APOE2, APOE3, APOE4, APOE5, APOE6, APOE7, APOE8, APOE9, APOE10, APOE11, APOE12, APOE13, APOE14, APOE15, APOE16, APOE17, APOE18, APOE19, APOE20, APOE21, APOE22, APOE23, APOE24, APOE25, APOE26, APOE27, APOE28, APOE29, APOE30, APOE31, APOE32, APOE33, APOE34, APOE35, APOE36, APOE37, APOE38, APOE39, APOE40, APOE41, APOE42, APOE43, APOE44, APOE45, APOE46, APOE47, APOE48, APOE49, APOE50, APOE51, APOE52, APOE53, APOE54, APOE55, APOE56, APOE57, APOE58, APOE59, APOE60, APOE61, APOE62, APOE63, APOE64, APOE65, APOE66, APOE67, APOE68, APOE69, APOE70, APOE71, APOE72, APOE73, APOE74, APOE75, APOE76, APOE77, APOE78, APOE79, APOE80, APOE81, APOE82, APOE83, APOE84, APOE85, APOE86, APOE87, APOE88, APOE89, APOE90, APOE91, APOE92, APOE93, APOE94, APOE95, APOE96, APOE97, APOE98, APOE99, APOE100	2%
Prostate cancer	16	10	4.88 × 10 <sup>4</sup>	10	62.5%	0.39	ABCA1, ABCG1, ABCG5, ABCG8, APOA1, APOA2, APOA5, APOB, APOE, APOE2, APOE3, APOE4, APOE5, APOE6, APOE7, APOE8, APOE9, APOE10, APOE11, APOE12, APOE13, APOE14, APOE15, APOE16, APOE17, APOE18, APOE19, APOE20, APOE21, APOE22, APOE23, APOE24, APOE25, APOE26, APOE27, APOE28, APOE29, APOE30, APOE31, APOE32, APOE33, APOE34, APOE35, APOE36, APOE37, APOE38, APOE39, APOE40, APOE41, APOE42, APOE43, APOE44, APOE45, APOE46, APOE47, APOE48, APOE49, APOE50, APOE51, APOE52, APOE53, APOE54, APOE55, APOE56, APOE57, APOE58, APOE59, APOE60, APOE61, APOE62, APOE63, APOE64, APOE65, APOE66, APOE67, APOE68, APOE69, APOE70, APOE71, APOE72, APOE73, APOE74, APOE75, APOE76, APOE77, APOE78, APOE79, APOE80, APOE81, APOE82, APOE83, APOE84, APOE85, APOE86, APOE87, APOE88, APOE89, APOE90, APOE91, APOE92, APOE93, APOE94, APOE95, APOE96, APOE97, APOE98, APOE99, APOE100	1%
Cystic fibrosis	22	10	1.04 × 10 <sup>4</sup>	10	45.5%	0.21	ABCA1, ABCG1, ABCG5, ABCG8, APOA1, APOA2, APOA5, APOB, APOE, APOE2, APOE3, APOE4, APOE5, APOE6, APOE7, APOE8, APOE9, APOE10, APOE11, APOE12, APOE13, APOE14, APOE15, APOE16, APOE17, APOE18, APOE19, APOE20, APOE21, APOE22, APOE23, APOE24, APOE25, APOE26, APOE27, APOE28, APOE29, APOE30, APOE31, APOE32, APOE33, APOE34, APOE35, APOE36, APOE37, APOE38, APOE39, APOE40, APOE41, APOE42, APOE43, APOE44, APOE45, APOE46, APOE47, APOE48, APOE49, APOE50, APOE51, APOE52, APOE53, APOE54, APOE55, APOE56, APOE57, APOE58, APOE59, APOE60, APOE61, APOE62, APOE63, APOE64, APOE65, APOE66, APOE67, APOE68, APOE69, APOE70, APOE71, APOE72, APOE73, APOE74, APOE75, APOE76, APOE77, APOE78, APOE79, APOE80, APOE81, APOE82, APOE83, APOE84, APOE85, APOE86, APOE87, APOE88, APOE89, APOE90, APOE91, APOE92, APOE93, APOE94, APOE95, APOE96, APOE97, APOE98, APOE99, APOE100	2%
Malaria resistance	20	10	3.28 × 10 <sup>4</sup>	10	50.0%	0.25	ABCA1, ABCG1, ABCG5, ABCG8, APOA1, APOA2, APOA5, APOB, APOE, APOE2, APOE3, APOE4, APOE5, APOE6, APOE7, APOE8, APOE9, APOE10, APOE11, APOE12, APOE13, APOE14, APOE15, APOE16, APOE17, APOE18, APOE19, APOE20, APOE21, APOE22, APOE23, APOE24, APOE25, APOE26, APOE27, APOE28, APOE29, APOE30, APOE31, APOE32, APOE33, APOE34, APOE35, APOE36, APOE37, APOE38, APOE39, APOE40, APOE41, APOE42, APOE43, APOE44, APOE45, APOE46, APOE47, APOE48, APOE49, APOE50, APOE51, APOE52, APOE53, APOE54, APOE55, APOE56, APOE57, APOE58, APOE59, APOE60, APOE61, APOE62, APOE63, APOE64, APOE65, APOE66, APOE67, APOE68, APOE69, APOE70, APOE71, APOE72, APOE73, APOE74, APOE75, APOE76, APOE77, APOE78, APOE79, APOE80, APOE81, APOE82, APOE83, APOE84, APOE85, APOE86, APOE87, APOE88, APOE89, APOE90, APOE91, APOE92, APOE93, APOE94, APOE95, APOE96, APOE97, APOE98, APOE99, APOE100	2%

<http://bejerano.stanford.edu> 7

### Individual Genomes → GREAT ?

Associate to nearest gene(s)

Personal cis variant → Target gene

Self reported medical summary → Any relationship? → Target gene

Is the group of affected target genes enriched for a particular function or phenotype?

Do individuals carry pathway specific cis-reg mutation load?  
Which binding sites?  
• Biochemically active ≠ functional  
• Under purifying selection  
From which context?  
The genome, which codes for all contexts.

<http://bejerano.stanford.edu> 8

### TF Motif Library (PBM+ChIP+SELEX)

motifs for 657 TFs

Known genes  
Genes with available motifs

<http://bejerano.stanford.edu> 9

### Predict conserved binding sites

= same as human

Human: TTTCCCTTAAAAGGCTTAAATAAATCACTCACCAGTGTTAATT  
Chimp: TTTCCCTTAAAAGGCTTAAATAAATCACTCACCAGTGTTAATT

- We in fact allow:
  - Imperfect matches
  - Binding site / alignment wobble
- Take measures against alignment fragmentations.
- Predict efficiently.
- Improve state of the art using "Excess conservation" scoring

<http://bejerano.stanford.edu> 10

### Compare everything to shuffled motifs & weed!

SRF motif: C C T T A A x G G  
 shuffle #1: C C C A A A C C T  
 shuffle #2: C C C T A A G C T  
 shuffle #3: C C A A C C G C T  
 shuffle #4: C C C T A A C C T  
 ...  
 shuffle #10: A T A A C C T C C

motif conservation curve

$-\log(\text{Probability})$  vs. motif conservation (substitutions / site)

[Wenger et al, Genome Research, 2013]

<http://bejerano.stanford.edu> 11

### PRISM vs. ChIP-seq → GREAT

SRF → Actin cytoskeleton

PRISM → Actin cytoskeleton ✓

ChIP-seq → Actin cytoskeleton ✓

Known: actin cytoskeleton

<http://bejerano.stanford.edu> 12

### PRISM vs. ChIP-seq → GREAT

Term	PRISM	ChIP-seq	Known
actin cytoskeleton	✓	✓	Known
structural constituent of muscle	✓	✗	Known
dilated heart ventricles	✓	✗	Known
regulation of insulin secretion	✓	✗	Novel

Every known function is supported by dozens or hundreds of novel binding sites.

Note: Sensitivity vs Specificity

<http://bejerano.stanford.edu> 13

### PRISM vs. ChIP-seq → GREAT

Term	PRISM	ChIP-seq	Known
actin cytoskeleton	✓	✓	Known
structural constituent of muscle	✓	✗	Known
dilated heart ventricles	✓	✗	Known
regulation of insulin secretion	✓	✗	Novel

Every known function is supported by dozens or hundreds of novel binding sites.

Note: Sensitivity vs Specificity

<http://bejerano.stanford.edu> 14

### GWAS SNPs: Predict upstream regulator

SNP	GWAS Phenotype	PRISM Binding Site	Mechanism of PRISM Factor to Phenotype	TF motif	Risk Allele Effect on Binding Site	Nearest Gene
rs1943	arterial blood lead level	GGTGG	SRF is a driver of endothelial dysfunction (Poulsen et al. 2012)	TF motif: <b>GGTGG</b> (GATA) Non-risk	↓	EDN1 (+596), EDN1 (-2046)
rs128331	prostate cancer	HGGAG	HOXB13 gene regulation results in abnormal prostate development (Pohland et al. 2008)	TF motif: <b>ATTTAAG</b> (ATTA) Non-risk	↑	HOXB13 (+276)
rs68918	breast cancer	GTG	Loss of ESR1 binding increases tumor susceptibility in mice (Wang et al. 2005)	TF motif: <b>TACC-C</b> (TACC) Non-risk	↑	TNFR2 (+146), SIRT6 (+274)
rs1058819	metabolic blood pressure	GGC	PP2A catalytic subunit binds to endothelial dysfunction (Miyamoto et al. 2005)	TF motif: <b>GGTATCA</b> (GAT) Non-risk	↓	PP2A (+104), SIRT6 (+158)
rs1281731	prostate cancer disease	GGG	SRF1 expression in prostate tumor is elevated in some but not all (Suzuki et al. 2007)	TF motif: <b>ACAGTCA</b> (ACA) Non-risk	↓	SRF1 (+84)

Huang et al. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat. Genet. 2014 Feb;46(2):126-135.

<http://bejerano.stanford.edu> 15

### Personal Deleterious Binding Sites

COBELs = Conserved Binding Site Eroding Loci

Individuals w public medical records

<http://bejerano.stanford.edu> 16

### COBELs → GREAT

Person	Affected phenotype	# of CoBELs	Fold Enrichment Rate (O-value)	Affected target genes	Fraction of relevant genes	Personal medical phenotype
Stephen Quate	abnormal cardiac output	57	2.00 (1.69 x 10 <sup>-11</sup> )	ADRA1A, ADRA1B, ARSE, CACNA1C, CD44, CD45, CD47, ELN, FN1, MYO10, MYO10-AS1, PDLIM1, PDLIM2, PDLIM3, PDLIM4, PDLIM5, PDLIM6, PDLIM7, PDLIM8, PDLIM9, PDLIM10, PDLIM11, PDLIM12, PDLIM13, PDLIM14, PDLIM15, PDLIM16, PDLIM17, PDLIM18, PDLIM19, PDLIM20, PDLIM21, PDLIM22, PDLIM23, PDLIM24, PDLIM25, PDLIM26, PDLIM27, PDLIM28, PDLIM29, PDLIM30, PDLIM31, PDLIM32, PDLIM33, PDLIM34, PDLIM35, PDLIM36, PDLIM37, PDLIM38, PDLIM39, PDLIM40, PDLIM41, PDLIM42, PDLIM43, PDLIM44, PDLIM45, PDLIM46, PDLIM47, PDLIM48, PDLIM49, PDLIM50, PDLIM51, PDLIM52, PDLIM53, PDLIM54, PDLIM55, PDLIM56, PDLIM57, PDLIM58, PDLIM59, PDLIM60, PDLIM61, PDLIM62, PDLIM63, PDLIM64, PDLIM65, PDLIM66, PDLIM67, PDLIM68, PDLIM69, PDLIM70, PDLIM71, PDLIM72, PDLIM73, PDLIM74, PDLIM75, PDLIM76, PDLIM77, PDLIM78, PDLIM79, PDLIM80, PDLIM81, PDLIM82, PDLIM83, PDLIM84, PDLIM85, PDLIM86, PDLIM87, PDLIM88, PDLIM89, PDLIM90, PDLIM91, PDLIM92, PDLIM93, PDLIM94, PDLIM95, PDLIM96, PDLIM97, PDLIM98, PDLIM99, PDLIM100	58%	family history of AF/DC and heart disease and abnormal cardiac output

<http://bejerano.stanford.edu> 17

### COBELs → GREAT

Person	Affected phenotype	# of CoBELs	Fold Enrichment Rate (O-value)	Affected target genes	Fraction of relevant genes	Personal medical phenotype
Stephen Quate	abnormal cardiac output	57	2.00 (1.69 x 10 <sup>-11</sup> )	ADRA1A, ADRA1B, ARSE, CACNA1C, CD44, CD45, CD47, ELN, FN1, MYO10, MYO10-AS1, PDLIM1, PDLIM2, PDLIM3, PDLIM4, PDLIM5, PDLIM6, PDLIM7, PDLIM8, PDLIM9, PDLIM10, PDLIM11, PDLIM12, PDLIM13, PDLIM14, PDLIM15, PDLIM16, PDLIM17, PDLIM18, PDLIM19, PDLIM20, PDLIM21, PDLIM22, PDLIM23, PDLIM24, PDLIM25, PDLIM26, PDLIM27, PDLIM28, PDLIM29, PDLIM30, PDLIM31, PDLIM32, PDLIM33, PDLIM34, PDLIM35, PDLIM36, PDLIM37, PDLIM38, PDLIM39, PDLIM40, PDLIM41, PDLIM42, PDLIM43, PDLIM44, PDLIM45, PDLIM46, PDLIM47, PDLIM48, PDLIM49, PDLIM50, PDLIM51, PDLIM52, PDLIM53, PDLIM54, PDLIM55, PDLIM56, PDLIM57, PDLIM58, PDLIM59, PDLIM60, PDLIM61, PDLIM62, PDLIM63, PDLIM64, PDLIM65, PDLIM66, PDLIM67, PDLIM68, PDLIM69, PDLIM70, PDLIM71, PDLIM72, PDLIM73, PDLIM74, PDLIM75, PDLIM76, PDLIM77, PDLIM78, PDLIM79, PDLIM80, PDLIM81, PDLIM82, PDLIM83, PDLIM84, PDLIM85, PDLIM86, PDLIM87, PDLIM88, PDLIM89, PDLIM90, PDLIM91, PDLIM92, PDLIM93, PDLIM94, PDLIM95, PDLIM96, PDLIM97, PDLIM98, PDLIM99, PDLIM100	58%	family history of AF/DC and heart disease and abnormal cardiac output

*Arrhythmogenic right ventricular dysplasia/cardiomyopathy is an inherited cardiomyopathy estimated to affect approximately 1 in 5,000 individuals. It is the disease is frequently fatal and typically involves substantial dominant transmission with low penetrance and variable expressivity.*

<http://bejerano.stanford.edu> 18

### COBELs → GREAT

Person	Affected phenotype	Personal genome based prediction			Affected target genes	Fraction of relevant genes	Personal medical phenotype
		# of COBEL loci	Fold	False Discovery Rate (FDR)			
Stephen Quake	abnormal cardiac output	37	2.33	$1.89 \times 10^{-27}$	ADRA1A, ADRA1B, ARSEL, CACMC2, CDAC2, CDAC3, CDAC4, ELN, FAN, MLVCD, NPFA, NPFB, PDLMD, PLN, PRFRAG1A, PRFRAG1B, RAFT1, ROR1A, TRMO1	56%	family history of AF/DC and heart disease and presumed sudden cardiac death
George Church	preganglionic parasympathetic nervous system development	23	3.26	$1.18 \times 10^{-22}$	EGFR, HES1, HES5, HCNX1, HCN2, HCN3, PULN4, TRAF3A	80%	nausea
Misha Angrist	epithelial cell morphogenesis	89	2.11	$1.38 \times 10^{-26}$	SAP1, BCL11B, BDNF, CTNNA1, EPB41L3, FZD7, GATA1, GDNF, GPR141, HES1, IGF1, PAX2, PAX6, SALL1, SLC2, WNT1	50%	possible keratosis pilaris

*\*Amylotrophic right ventricular dysplasia/cardiomyopathy is an inherited cardiomyopathy estimated to affect approximately 1 in 5,000 individuals. [1] The disease is frequently familial and typically involves autosomal dominant transmission with low penetrance and variable expressivity. [2]*

*\*... a non-secondary involvement of the autonomic nervous system in nausea is strongly suggested [3]*

*\*The epidermis (in keratosis pilaris) demonstrates mild hyperkeratosis, hypergranulosis, and follicular plugging [4]*

<http://bejerano.stanford.edu> 19

### COBELs → GREAT

Person	Affected phenotype	Personal genome based prediction			Affected target genes	Fraction of relevant genes	Personal medical phenotype
		# of COBEL loci	Fold	False Discovery Rate (FDR)			
Stephen Quake	abnormal cardiac output	37	2.33	$1.89 \times 10^{-27}$	ADRA1A, ADRA1B, ARSEL, CACMC2, CDAC2, CDAC3, CDAC4, ELN, FAN, MLVCD, NPFA, NPFB, PDLMD, PLN, PRFRAG1A, PRFRAG1B, RAFT1, ROR1A, TRMO1	56%	family history of AF/DC and heart disease and presumed sudden cardiac death
George Church	preganglionic parasympathetic nervous system development	23	3.26	$1.18 \times 10^{-22}$	EGFR, HES1, HES5, HCNX1, HCN2, HCN3, PULN4, TRAF3A	80%	nausea
Misha Angrist	epithelial cell morphogenesis	89	2.11	$1.38 \times 10^{-26}$	SAP1, BCL11B, BDNF, CTNNA1, EPB41L3, FZD7, GATA1, GDNF, GPR141, HES1, IGF1, PAX2, PAX6, SALL1, SLC2, WNT1	50%	possible keratosis pilaris

*\*Amylotrophic right ventricular dysplasia/cardiomyopathy is an inherited cardiomyopathy estimated to affect approximately 1 in 5,000 individuals. [1] The disease is frequently familial and typically involves autosomal dominant transmission with low penetrance and variable expressivity. [2]*

*\*... a non-secondary involvement of the autonomic nervous system in nausea is strongly suggested [3]*

*\*The epidermis (in keratosis pilaris) demonstrates mild hyperkeratosis, hypergranulosis, and follicular plugging [4]*

<http://bejerano.stanford.edu> 20

### COBELs → GREAT

Person	Affected phenotype	Personal genome based prediction			Affected target genes	Fraction of relevant genes	Personal medical phenotype
		# of COBEL loci	Fold	False Discovery Rate (FDR)			
Stephen Quake	abnormal cardiac output	37	2.33	$1.89 \times 10^{-27}$	ADRA1A, ADRA1B, ARSEL, CACMC2, CDAC2, CDAC3, CDAC4, ELN, FAN, MLVCD, NPFA, NPFB, PDLMD, PLN, PRFRAG1A, PRFRAG1B, RAFT1, ROR1A, TRMO1	56%	family history of AF/DC and heart disease and presumed sudden cardiac death
George Church	preganglionic parasympathetic nervous system development	23	3.26	$1.18 \times 10^{-22}$	EGFR, HES1, HES5, HCNX1, HCN2, HCN3, PULN4, TRAF3A	80%	nausea
Misha Angrist	epithelial cell morphogenesis	89	2.11	$1.38 \times 10^{-26}$	SAP1, BCL11B, BDNF, CTNNA1, EPB41L3, FZD7, GATA1, GDNF, GPR141, HES1, IGF1, PAX2, PAX6, SALL1, SLC2, WNT1	50%	possible keratosis pilaris
Reazayee Gill	decreased circulating sodium level (hypohydratemia)	32	3.23	$4.84 \times 10^{-22}$	EDN1, HNSC2, SCHN1B, SCHN1C, SLC22A1, SLC22A2, TRAP, WNK3	80%	hypertension

*\*Amylotrophic right ventricular dysplasia/cardiomyopathy is an inherited cardiomyopathy estimated to affect approximately 1 in 5,000 individuals. [1] The disease is frequently familial and typically involves autosomal dominant transmission with low penetrance and variable expressivity. [2]*

*\*... a non-secondary involvement of the autonomic nervous system in nausea is strongly suggested [3]*

*\*The epidermis (in keratosis pilaris) demonstrates mild hyperkeratosis, hypergranulosis, and follicular plugging [4]*

*\*A sodium-conserving gene in the context of the cardiovascular high-sodium and low-potassium diet is maladaptive, with documented pathological and epidemiological consequences (i.e. systemic hypertension) [5]*

<http://bejerano.stanford.edu> 21

### COBELs → GREAT

Person	Affected phenotype	Personal genome based prediction			Affected target genes	Fraction of relevant genes	Personal medical phenotype
		# of COBEL loci	Fold	False Discovery Rate (FDR)			
Stephen Quake	abnormal cardiac output	37	2.33	$1.89 \times 10^{-27}$	ADRA1A, ADRA1B, ARSEL, CACMC2, CDAC2, CDAC3, CDAC4, ELN, FAN, MLVCD, NPFA, NPFB, PDLMD, PLN, PRFRAG1A, PRFRAG1B, RAFT1, ROR1A, TRMO1	56%	family history of AF/DC and heart disease and presumed sudden cardiac death
George Church	preganglionic parasympathetic nervous system development	23	3.26	$1.18 \times 10^{-22}$	EGFR, HES1, HES5, HCNX1, HCN2, HCN3, PULN4, TRAF3A	80%	nausea
Misha Angrist	epithelial cell morphogenesis	89	2.11	$1.38 \times 10^{-26}$	SAP1, BCL11B, BDNF, CTNNA1, EPB41L3, FZD7, GATA1, GDNF, GPR141, HES1, IGF1, PAX2, PAX6, SALL1, SLC2, WNT1	50%	possible keratosis pilaris
Reazayee Gill	decreased circulating sodium level (hypohydratemia)	32	3.23	$4.84 \times 10^{-22}$	EDN1, HNSC2, SCHN1B, SCHN1C, SLC22A1, SLC22A2, TRAP, WNK3	80%	hypertension
James Lupski	regulation of oligodendrocyte differentiation	28	2.11	$2.93 \times 10^{-21}$	ADRA1A, ADRA1B, CDAC2, CDAC3, CDAC4, ELN, FAN, HCN2, HCN3, HES1, IGF1, LINC01, OLIG2, PFRAN1, SIRT1, SIRT2	70%	family history of pterygia and peripheral neuropathy

*\*Amylotrophic right ventricular dysplasia/cardiomyopathy is an inherited cardiomyopathy estimated to affect approximately 1 in 5,000 individuals. [1] The disease is frequently familial and typically involves autosomal dominant transmission with low penetrance and variable expressivity. [2]*

*\*... a non-secondary involvement of the autonomic nervous system in nausea is strongly suggested [3]*

*\*The epidermis (in keratosis pilaris) demonstrates mild hyperkeratosis, hypergranulosis, and follicular plugging [4]*

*\*A sodium-conserving gene in the context of the cardiovascular high-sodium and low-potassium diet is maladaptive, with documented pathological and epidemiological consequences (i.e. systemic hypertension) [5]*

*\*Oligodendrocytes, the myelin-forming glial cells of the central nervous system, maintain long-term axonal integrity [6]*

<http://bejerano.stanford.edu> 22

### Randomize COBELs

- Replace every CoBEL with a random binding site prediction for the same transcription factor of a same affinity and similar cross-species conservation.
- Using 10,000 random control sets, the likelihood of obtaining the functions reported in Table 1 as top prediction due to bias in the distribution of binding sites in the genome is low (Quake P = 3 x 10<sup>-4</sup>, Church P = 5.7 x 10<sup>-3</sup>, Angrist P = 4.8 x 10<sup>-3</sup>, Gill P = 1 x 10<sup>-4</sup>, Lupski P = 1.9 x 10<sup>-3</sup>, and combined P = 1.6 x 10<sup>-15</sup>).
- Significance remains high when we relax the requirement to recover each exact same term with matching any one of a broader group of 12-60 related functions as a top prediction (Quake P = 1.1 x 10<sup>-3</sup>, Church P = 1.3 x 10<sup>-2</sup>, Angrist P = 7.7 x 10<sup>-3</sup>, Gill P = 7.4 x 10<sup>-3</sup>, Lupski P = 6.5 x 10<sup>-3</sup>, and combined P = 5.2 x 10<sup>-12</sup>).

<http://bejerano.stanford.edu> 23

### KGP as Controls

Person	Top Prediction	Top Prediction P-value	Top Prediction FDR	Top Prediction FDR (Relaxed)
Quake	abnormal cardiac output	1.89e-27	0.0001	0.0001
Church	preganglionic parasympathetic nervous system development	1.18e-22	0.0001	0.0001
Angrist	epithelial cell morphogenesis	1.38e-26	0.0001	0.0001
Gill	decreased circulating sodium level (hypohydratemia)	4.84e-22	0.0001	0.0001
Lupski	regulation of oligodendrocyte differentiation	2.93e-21	0.0001	0.0001

<http://bejerano.stanford.edu> 24

### Randomize Medical Histories

- Define an **association matrix linking enrichment and medical history**, with the phenotypes observed in the five individuals as rows, and top enriched terms in all as columns. A cell in the matrix would be marked "true" only where the enriched term (of any individual) is thought to be related to the etiology of the phenotype (of any individual).
- One instance of this matrix was filled by a **medical doctor** based on their medical knowledge and training and another instance was independently filled using a **literature survey**. The objective was to compute the chance of associating a set of five individuals with random medical histories with the observed enrichments using one of the two association matrices as the "gold" association.
- We generated 1,000 sets of five individuals with random medical histories composed of similar disease profiles and assessed the likelihood of being able to associate them with enrichments. Successfully linking five random individuals with enrichments was highly significant using the association matrix generated by the **medical doctor** ( $P = 3.0 \times 10^{-3}$ ) and by the matrix generated by **literature survey** ( $P = 3.0 \times 10^{-2}$ ) suggesting our links between enrichment and medical histories are not just a function of the listed histories.

<http://bejerano.stanford.edu> 25

### COBELs ≠ GWAS SNPs or HGMD

Person	Affected phenotype	Personal genome based prediction			Affected target genes	Fraction of relevant genes	Personal medical genotype
		# of COBELs	Fold	False Discovery Rate (FDR)			
Stephen Quake	abnormal cardiac output	27	2.23	$1.93 \times 10^{-4}$	ADRA1A, ADRA1B, AP5B, CACNA2, CACNA3, CACNA3B, CACNA3C, EDA, PVALB, ACEL, NPYA, NPXD, PDLIM3, PDLN, PRKRA3CA, PRKRA3CB, SNTF1, NORA, TM6SF1	56%	family history of AFIB/EC and heart disease and personal cardiac death
George Church	paraganglioma; parasympathetic nervous system development	23	3.28	$1.18 \times 10^{-4}$	EDG2, HES1, HES5, HOUA1, HES6L, HES6C, PUM1A, TRAF3A	85%	nasopharynx
Melita Angriani	epithelial cell neoplasms	20	2.11	$1.38 \times 10^{-4}$	DAP3, BCL11B, BMP4, CTNNA1, ERBB3L1, E2F7, GATA3, GSNF, GSNM1, HES1, IGF1, PAX6, PAX6, SALL1, SIRT1, WNT1	59%	possible hereditary photos
Rebecca Gill	decreased circulating insulin level (hypoglycemia)	22	3.23	$4.84 \times 10^{-4}$	EDN1, NFKB2, SCOR1B, SCOR1B, SCOR1B, SCOR1A, TNFR1, TNFR2	86%	hypertension
James Lupski	regulation of oligodendrocyte differentiation	28	2.11	$2.83 \times 10^{-4}$	ASPA, BMP4, CTNNA1, CACNA, CLY1, CLY1, HES1, HES2, IGF1, LINGO1, DUGL1, PRKRA3, SNTF1	73%	family history of epilepsy and/or neurodegeneration

<http://bejerano.stanford.edu> 26

### Most Predictive COBELs are Private

<http://bejerano.stanford.edu> 27

### Contributions from Common & Rare

Subset to 1% freq in KGP → lose all enrichments

<http://bejerano.stanford.edu> 28

### Summary

- We define likely deleterious events as personal variants that erode the affinity of human conserved binding sites.
- When the set of all such events is probed for lying next to gene sets of particular function or phenotype, we repeatedly get a solid match between top genomic prediction and self reported medical summary.
- Top genomic predictions are eroded at both gene and gene set level.
- The variants we highlight appear to be part of the mutational load pre-disposing individual lineages to different diseases.

**COBELs**

<http://bejerano.stanford.edu> 29

### Other Lab Interests: 1) Solve Patient

<http://bejerano.stanford.edu> 30

### 2) Automate Patient Solving

Genes:

$$\begin{matrix} g_1 \\ g_2 \\ \vdots \end{matrix}$$

phenotypes:

$$\begin{matrix} \phi_1 \\ \phi_2 \\ \vdots \end{matrix}$$

$$\begin{matrix} \vdots \\ g_{100} & \phi_{1000} \\ g_{53} & \phi_{500} \\ \uparrow \text{learn} \\ \text{features} \end{matrix}$$

$g_1 - \phi_2$	$g_2 - \phi_2$	✓	
$g_2 - \phi_4$	$g_2 - \phi_4$	✓	
$g_2 - \phi_7$	$g_2 - \phi_7$	✗	

<http://bejerano.stanford.edu> 31

### 3) Discover Mammalian Adaptations

Output

Program = Genome

<http://bejerano.stanford.edu> 32

### Kudos

---

COBELS: (PLoS Comp Bio, 2016)  
**Harendra Guturu**, Sandeep Chinchali, Shoa Clarke

PRISM: (Genome Research, 2013)  
 Aaron Wenger, Shoa Clarke, Harendra Guturu, Jenny Chen, Bruce Schaar, Cory McLean

GREAT: (Nature Biotechnology, 2010)  
 Cory McLean, Dave Bristor, Michael Hiller, Shoa Clarke, Bruce Schaar, Craig Lowe, Aaron Wenger

Bejerano Lab past & present
The Organizers

<http://bejerano.stanford.edu> 33

---

<http://bejerano.stanford.edu> 34